CA
OCUL icon

Cliff Asness’s Ocular Therapeutix OCUL Stock Holding History

Cliff Asness’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.33M Buy
950,338
+450,999
+90% +$4.09M ﹤0.01% 1611
2026
Q1 		$4.23M Buy
499,339
+318,616
+176% +$3.04M ﹤0.01% 1859
2025
Q4 		$2.19M Buy
180,723
+34,847
+24% +$423K ﹤0.01% 2080
2025
Q3 		$1.71M Buy
145,876
+34,854
+31% +$417K ﹤0.01% 2080
2025
Q2 		$1.03M Buy
111,022
+95,372
+609% +$746K ﹤0.01% 2194
2025
Q1 		$115K Sell
15,650
-10,629
-40% -$81.7K ﹤0.01% 2992
2024
Q4 		$224K Buy
26,279
+8,791
+50% +$85.8K ﹤0.01% 2626
2024
Q3 		$152K Buy
+17,488
New +$144K ﹤0.01% 2615
2024
Q2 		– Sell
-11,755
Closed -$107K – 2655
2024
Q1 		$107K Sell
11,755
-40,473
-77% -$287K ﹤0.01% 2332
2023
Q4 		$233K Sell
52,228
-14,976
-22% -$44.3K ﹤0.01% 2159
2023
Q3 		$211K Buy
67,204
+24,974
+59% +$102K ﹤0.01% 2126
2023
Q2 		$218K Sell
42,230
-288
-0.7% -$1.71K ﹤0.01% 2062
2023
Q1 		$224K Sell
42,518
-70,092
-62% -$333K ﹤0.01% 2020
2022
Q4 		$316K Buy
112,610
+99,628
+767% +$330K ﹤0.01% 1956
2022
Q3 		$54K Sell
12,982
-22,360
-63% -$113K ﹤0.01% 2146
2022
Q2 		$142K Buy
35,342
+6,947
+24% +$26.2K ﹤0.01% 2044
2022
Q1 		$141K Buy
28,395
+6,675
+31% +$37K ﹤0.01% 2109
2021
Q4 		$151K Sell
21,720
-42,962
-66% -$334K ﹤0.01% 2122
2021
Q3 		$647K Buy
64,682
+6,007
+10% +$67.5K ﹤0.01% 1761
2021
Q2 		$832K Sell
58,675
-6,402
-10% -$97.3K ﹤0.01% 1661
2021
Q1 		$1.07M Buy
65,077
+16,291
+33% +$314K ﹤0.01% 1521
2020
Q4 		$1.01M Sell
48,786
-7,829
-14% -$116K ﹤0.01% 1504
2020
Q3 		$431K Sell
56,615
-16,595
-23% -$138K ﹤0.01% 1792
2020
Q2 		$610K Buy
+73,210
New +$485K ﹤0.01% 1672
2017
Q4 		– Sell
-21,256
Closed -$131K – 2261
2017
Q3 		$131K Buy
+21,256
New +$137K ﹤0.01% 2215

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cliff Asness's OCUL Position: Q2 2026 in Review

Cliff Asness increased its Ocular Therapeutix (OCUL) stake by 90% in Q2 2026, buying an estimated $4.09M and bringing the position to 950,338 shares worth $9.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

Cliff Asness first reported a position in OCUL in Q3 2017 and has held it in 25 quarters since. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Cliff Asness held 950,338 shares of Ocular Therapeutix worth $9.33M as of Q2 2026.
  • Cliff Asness bought 450,999 Ocular Therapeutix shares in Q2 2026, an estimated $4.09M.
  • Ocular Therapeutix made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1611 holding.
  • Cliff Asness first reported a position in Ocular Therapeutix in Q3 2017 and has held it in 25 quarters since.
  • 260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.